Use of genomic testing and ketogenic compounds for treatment of reduced cognitive function

• US 9,175,345 B2
• Filed: 07/31/2008
• Issued: 11/03/2015
• Est. Priority Date: 07/31/2007
• Status: Active Grant

• Current Assignee: Cerecin, Inc.
• Original Assignee: Accela Incorporated (Piksel Incorporated)
• Inventors: Henderson, Samuel T.
• Primary Examiner(s): SITTON, JEHANNE SOUAYA
• Application Number:
  US12/671,610
• Publication Number:
  US 20110243885A1
• Time in Patent Office: 2,651 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61K 31/23 of acids having a carboxyl group bound to a chain of seven or more carbon atoms
• CPC Class Codes: A61K 31/7004 Monosaccharides having only carbon, hydrogen and oxygen atoms
• CPC Class Codes: A61P 25/08 Antiepileptics; Anticonvulsants
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/106 Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: C12Q 2600/158 Expression markers

Abstract

This invention relates to methods of using genotyping to select patients for treatment with compounds capable of elevating ketone body concentrations in amounts effective to treat reduced neuronal metabolism associated with reduced neuronal metabolism, for example Alzheimer'"'"'s disease.

Claims

1. A method of treatment for Alzheimer'"'"'s disease, comprising the steps of:

a. selecting a human patient having, or at risk of Alzheimer'"'"'s disease;

b. determining in the patient the presence of at least one of the specific genotypes selected from the group consisting of;

i. heterozygosity for C/T for Insulin Degrading Enzyme (IDE) rs 2251101 at relevant portion shown by SEQ ID NO;

3, and

ii. absence of homozygosity for C/C of IDE rs 2251101 at relevant portion shown by SEQ ID NO;

3; and

administering to the patient having at least one of the specific genotypes in (b a composition comprising an effective amount of medium chain triglycerides (MCT) of the formula;

2. The method of claim 1, wherein the method further comprises testing the patient for the absence of ApoE4 genotype.

3. The method of claim 1, wherein the composition is an oral composition which further comprises glucose.

4. The method of claim 1, wherein the composition is administered in an amount effective to raise the blood level of D-beta-hydroxybutyrate in the patient from about 0.1 mM to about 50 mM.

5. The method of claim 1, wherein the composition is administered in an amount effective to raise the blood level of D-beta-hydroxybutyrate in the patient from about 0.2 mM to about 5 mM.

6. The method of claim 1, wherein the composition is administered at a dose of about 0.05 g/kg/day to about 10 g/kg/day.